Pharma Surge
Pharma Surge
Intelligence Layer
🇺🇸·May 4Research

Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential

Publisher

O
OrbiMed

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
OrbiMed
Region
USA
Scope
Research
Published
May 4, 2026

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on orbimed.com

Leave the platform to read the original full article on the publisher site.

Source: OrbiMed

Scope: Research

Open original article
Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential | Pharma Surge